Pharmaceutical glassmaker Schott has completed the next expansion stage at its new pharmaceutical glass tubing site in Jinyun, China.
The plant started its production in November 2020 after only 15 months ramp-up period.
It was officially inaugurated with customers and government representatives in summer 2021 and supplies high-quality borosilicate glass tubing to produce pharma containers that store vaccines (e.g., against COVID-19) and other drugs.
"Right on schedule with our planning, we have doubled our melting capacity. It's another big milestone for pharma tubing in China.
Dr. Patrick Markschläger, Executive Vice President of Schott's Business Unit Tubing said: “The expanded infrastructure will enable a reliable local supply of glass tubing, which is needed urgently to serve the increased demand for pharmaceutical packaging.
SCHOTT has established a production base for borosilicate glass tubing in Jinyun as a supply hub for the local Chinese market.
The construction of the site was completed after just 15 months despite the pandemic.
The plant in Jinyun created so far 250 new jobs and enabled an improved supply chain, which will subsequently help enhance the packaging quality.
Dr. Markschläger added: "This new site marks the first time our company is melting glass in China.
“It's our commitment to help bring the government's vision of "Healthy China 2030" into reality."
Schott has invested €60 million in this Chinese tubing plant as part of a worldwide $1 billion pharma business investment programme.
